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DNA/RNA. In both human and canine brain, oxidative damageprogressively increaseswith age. In theAlzheimer's
disease (AD) brain, oxidative damage is further exacerbated, possibly due to increaseddeposition of beta-amyloid
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are a useful animal model in which to test antioxidants. In a longitudinal study of aging beagles, a diet rich in an-
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animals. These data suggest that antioxidants may be beneﬁcial for human brain aging and for AD, particularly as
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Progressive oxidative damage is a consistent feature of aging [1–4].
The brain is particularly vulnerable to oxidative damage, as it is consumes
approximately 20% of the body's total oxygen, has a high content of poly-
unsaturated fatty acids and has lower levels of endogenous antioxidant
activity relative to other tissue [5–7]. Normal metabolic processes result
in the release of reactive oxygen species (ROS), which in turn can lead
to oxidative damage to proteins, lipids, DNA and RNA [1]. ROS are pro-
duced primarily from mitochondria [8], intracellular organelles that are
themselves vulnerable to oxidative damage [9]. The combination ofmito-
chondrial dysfunction and production of ROSmay be a key contributor to
the deleterious effects of aging on the brain [10–18].
Studies of normal human brain aging provide correlative evidence
suggesting that oxidative damage plays a role in age-associated cog-
nitive losses. Studies of human autopsy tissue show higher levels of
oxidative damage to nucleic acids [19–21], proteins [20,22–25] and
lipids [21,25,26] in aged brain as compared to young brain. Mitochon-
drial function also appears compromised with age in the human brain
[3,4,14,27]. In normal aging, mitochondrial respiratory chain activity
declines [28], mitochondrial metabolism-associated enzymes such
as aconitase decrease [29] and the rate of somatic mitochondrialDNA mutations increases [17,30]. Thus, mitochondrial dysfunction
and the production of ROS, combined with lower endogenous antiox-
idant activity, may lead to increasing oxidative damage to molecules
critically important to neuronal function.
2. Oxidative stress and Alzheimer's disease
Oxidative damage may also play a role in age-associated neurode-
generative diseases such as Alzheimer's disease (AD) [31–33]. AD is a
progressive neurodegenerative disease that causes dementia in the
elderly. AD is characterized by the accumulation of beta-amyloid
(Aβ) in extracellular senile plaques and intracellular hyperpho-
sphorylated tau protein in neuroﬁbrillary tangles [34]. Consequently,
extensive neuron loss is observed in the AD brain in the cortex and
particularly within the hippocampus, a region of the brain involved
with memory. AD is associated with further increases in oxidative
damage to protein [20,23,24,35–42], lipid [21,26,43–46], DNA [47–
49] and RNA [12,50,51] relative to elderly controls. In addition, en-
dogenous antioxidant activity in the AD brain is reduced relative to
age-matched controls [20,25,52]. Proteins particularly vulnerable to
oxidative damage have been identiﬁed by proteomics, with a subset
of these proteins putatively involved directly or indirectly in the pro-
duction and accumulation of AD neuropathology [53]. Mitochondrial
dysfunction also occurs in AD, with decreased respiratory chain activ-
ity [15,54,55] and increased mitochondrial DNA mutations [56] ob-
served at higher rates when compared to age-matched controls.
Further, decreased cytochrome oxidase activity in the posterior cin-
gulate cortex of AD patients is correlated with hypometabolism
seen by positron emission studies [57]. A gene array study in the cin-
gulate cortex shows that energy-metabolism related genes decrease
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transport chain genes [58].
Based on correlative human neuropathology studies, antioxidants
are predictive of healthy aging, may reduce the risk of developing AD
and may improve cognitive function in AD patients. However, studies
in humans have shown either a positive effect of antioxidant use on
cognition and risk reduction for developing AD [59–61] or no signiﬁ-
cant effects [62–65]. Few systematic and controlled clinical trials have
evaluated the effects of antioxidants on cognition in aged individuals
or patients with AD. Intake of vitamin E delays institutionalization in
AD patients [66], suggesting some beneﬁcial effects. However, vita-
min E alone did not improve cognition in patients with mild cognitive
impairment, which is thought to precede AD [67]. Further, in non-
demented elderly women, vitamin E treatment was associated with
little improvement in cognition [64].
In addition to investigating the effects of cellular antioxidants on cog-
nition and risk of AD, several studies examined the effects of targeted co-
factors that improve mitochondrial function, including acetylcarnitine
(ALCAR) and lipoic acid (LA). ALCAR and LAmay improvemitochondrial
function and reduce the production of ROS, thus also reducing oxidative
damage to proteins, lipids and DNA/RNA [68]. In studies where ALCAR
was administered to patients with moderate to severe AD, either im-
proved cognition and/or slower deterioration was observed [69–72]. In
early-onset AD patients (less than 65 years of age), only small cognitive
improvements were noted [73], although younger patients with AD
(less than 61 years) may also have experienced slowed disease progres-
sion [74,75]. When the results of all these studies are combined in a
meta-analysis, ALCAR administration in patients with AD was clearly
beneﬁcial, particularly with respect to slowing cognitive decline [76].
Further, combining ALCAR with acetylcholinesterase therapy in AD
may provide additional beneﬁts [77]. Similar evidence of maintenance
of function was observed in an open label study of 9 patients with AD
or related dementias receiving 600 mg/day of LA for an average of
337 days [78]. In a larger follow up study of 48 patients for a 48 month
treatment period, maintenance of function was also observed [79].
Taken together, studies of dietary or supplemental antioxidant in-
take in humans reveal variable results and appear far less robustly as-
sociated with positive functional outcomes than those reported in the
rodent aging literature [9,18,80–87]. Variability in the outcomes of
human antioxidant clinical trials outcomes may reﬂect inconsis-
tencies in the amount of supplements provided, their form and source
(e.g. lower AD brain neuropathology is associated with cerebrospinal
ﬂuid levels of alpha-tocopherol and not gamma-tocopherol [88]),
their duration and regularity of use and challenges in determining
the exact background of dietary antioxidants [89]. Interestingly,
combinations of antioxidants may be superior to single compound
supplementation [90] and dietary intake of antioxidants is superior
to supplements in human studies on cognition and risk of developing
AD [91,92]. Further, supplementation of elderly womenwith a combi-
nation of vitamins E and C can lead to improved memory [93]. Thus,
antioxidants may prove to be more efﬁcacious if administered in
combination with other antioxidants (e.g. vitamin C, which helps to
recycle Vitamin E) and through diet, rather than as a supplement.
A panel of experts for the Duke Evidence-based Practice Center for
the US Department of Health and Human Services recently reviewed
the literature and, not surprisingly, reported no consistent or robust ev-
idence to suggest that single or dual antioxidant use is protective against
AD [94]. In terms of preventing cognitive decline with aging, vegetable
intake was only weakly associated with decreased risk of developing
AD, whereas cognitive training was strongly associated with decreased
risk. Thus, the role of either dietary or supplemental antioxidants and
level of protection against cognitive decline or AD has yet to be clearly
established. Additional reasons for the small or negative effects of anti-
oxidants on cognition in the elderly and for treatment of AD [80,95] in-
clude the limitations of animal models (primarily rodent) in terms of
ability to predict human response. Therefore, it is useful to considerother animal models of human aging and AD, and also to test the poten-
tial for combinations of antioxidants/ mitochondrial co-factors to im-
prove cognition and reduce Aβ. Speciﬁcally, dogs are frequently used
to evaluate safety of drugs and in food metabolism studies given their
substantial similarities to humans.3. Studies in aged dogs
Dogs may be particularly useful in studying human brain aging be-
cause they naturally develop cognitive declinewith age, accumulate ox-
idative damage and Aβ protein [96]. In dog brain, oxidative damage to
proteins increases with age [97,98] and is associated with reduced en-
dogenous antioxidant enzyme activity or protein levels [97,99–101].
In several studies, a relation between age and increased oxidative dam-
age has been inferred bymeasuring the amount of end products of lipid
peroxidation to predict oxidative damage to lipids. These end products
include 4-hydroxynonenal [101–104] and malondialdehyde [97]. Addi-
tionally, we and others have reported evidence of increased oxidative
damage to DNA or RNA (8OHdG) in aged dog brain [96,104].
Oxidative damage may also be associated with behavioral decline
in dogs. Roﬁna and collaborators examined oxidative end products
(lipofuscin-like pigment and protein carbonyls) in aged companion
dog brain [98,103,104] and found a correlation between increased ox-
idative end products and severity of behavior changes due to cogni-
tive dysfunction. Similarly, in our own studies of aging beagles,
higher protein oxidative damage (3-nitrotyrosine) and lower endog-
enous antioxidant capacity (superoxide dismutase and glutathione-S-
transferase) are associated with poorer prefrontal-dependent and
spatial learning [100]. These correlative studies suggest a link be-
tween cognition and progressive oxidative damage in the dog, sug-
gesting their utility in testing antioxidant treatment strategies.
To test the hypothesis that reduced oxidative stress leads to cogni-
tive beneﬁts, we implemented a longitudinal study of aged dogs. In
this study, a combination of antioxidants and mitochondrial co-factors
was provided in food [105–109]. 48 aged beagles (between ~8 and
12 years) were divided into four groups that were balanced with
respect to baseline cognitive ability, sex and age: (1) no behavioral
enrichment/control diet group; (2) behavioral enrichment/control
diet; (3) no behavioral enrichment/antioxidant diet; and (4) combined
behavioral enrichment and antioxidant diet. In a subset of experiments,
an additional 17 young beagles (b5 years of age) were included for
comparison to aged dogs. Young dogs were all placed in the behavioral
enrichment condition, with half provided with the antioxidant diet (i.e.
similar to groups 2 and 4).
Three unique features of the experiment included: 1) a combination
of antioxidants andmitochondrial co-factors; 2) incorporation of all an-
tioxidants and mitochondrial co-factors into food and; 3) evaluation of
dietary treatments in combination with behavioral enrichment. An an-
tioxidant-enriched dog diet was formulated to include a broad spec-
trum of antioxidants and two mitochondrial co-factors [108]. Based on
an average weight of 10 kg per animal, the daily doses for each com-
pound were 800 IU or 210 mg/day (21 mg/kg/day) of vitamin E,
16 mg/day (1.6 mg/kg/day) of vitamin C, 52 mg/day (5.2 mg/kg/day)
of carnitine and 26mg/day (2.6 mg/kg/day) of lipoic acid. Fruits and
vegetables were also incorporated at a 1 to 1 exchange ratio for corn,
resulting in 1% inclusions (dehydrated) of each of the following: spin-
ach ﬂakes, tomato pomace, grape pomace, carrot granules and citrus
pulp. This was equivalent to raising fruits and vegetable intake from 3
servings per day to 5–6 servings per day based upon ORAC values
[110]. Additionally, vitamin E was increased by ~75% in dogs treated
with the antioxidant diet [111]. The behavioral enrichment condition
consisted of additional cognitive experience (20–30 min/day, 5 day-
s/week), an enriched sensory environment (housing with a kennel-
mate, weekly rotation of play toys in kennel) and physical exercise
(two 20 min outdoor walks/week) [108].
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and chronic treatment effects. Treatment with the antioxidant diet
leads to cognitive improvements in learning within two weeks, with
aged animals showing signiﬁcant improvements in spatial attention
(landmark task) [111]. Subsequent testing of animals with a more dif-
ﬁcult complex learning task (oddity discrimination) also revealed
beneﬁts of the diet [105]. With antioxidant treatment, visual discrim-
ination improved and reversal (frontal function) learning ability was
maintained over time while untreated animals showed a progressive
decline [108]. This was despite the fact that for each time point where
discrimination learning was re-administered, the task was made
more difﬁcult (harder to distinguish objects) to prevent a practice ef-
fect. Thus the progressive increase in error scores over time in
untreated dogs reﬂects both increased task difﬁculty and possibly,
longitudinal aging effects. Interestingly, the dogs fed an antioxidant
diet beneﬁted from behavioral enrichment, in that cognitive scores
of aged dogs receiving both treatments were superior to either treat-
ment alone [107,108]. For example, in singly treated animals spatial
memory showed a trend toward improvement, reaching statistical
signiﬁcance only after long-term treatment (>2 years) with a combi-
nation of both the antioxidant diet and behavioral enrichment [109].
The antioxidant diet selectively repaired an aging deﬁcit, in that cog-
nitive scores from young dogs treated with the antioxidant diet did
not differ from those of young dogs fed control diet [112].
Neurobiological studies showed reduced oxidative damage and
increased endogenous antioxidant activity in antioxidant-fed dogs,
particularly among animals receiving the combination of antioxidants
and behavioral enrichment [100]. Interestingly, the antioxidant diet
increased the levels of glutathione suggesting a possible involvement
of a possible vitagene network that might account for the increased
expression of antioxidant molecules and growth proteins [113,114].
Given that the diet provided to the dogs also included acetylcarnitine,
resulting in increased levels of HO-1 also support the possibility that
vitagene networks are engaged [113].
Mitochondrial function was signiﬁcantly improved in the antioxi-
dant fed dogs and not in behaviorally enriched dogs [115]. Interest-
ingly, behavioral enrichment but not the antioxidant diet protected
against neuron loss in the hilus of the dog hippocampus [116]. Fur-
ther, brain derived neurotrophic factor mRNA increased in aged
dogs provided with the combination treatment [117]. These results
suggest that cognitive beneﬁts of antioxidants can be further en-
hanced with the addition of behavioral enrichment, perhaps due to
different yet synergistic mechanisms of action in the brain, including
reduced oxidative damage and maintenance of neuron health. In ad-
dition to brain, however, peripheral beneﬁts were also seen, including
less cellular degeneration in the inner ear [118].
Interestingly, in a recent study of aged dogs, the formulation of the
diet was modiﬁed to compare only the mitochondrial co-factors used
in this previous study and effects on cognition [119]. Aged dogs were
treated with lipoic acid, ALCAR or the combination and tested with spa-
tial learning and discrimination/reversal tasks. When these compounds
were included with a broader spectrum of antioxidants described
above, no cognitive beneﬁts were observed when evaluated singly or
in combination. Additionally, protein carbonyl accumulation in the
plasma of treated dogs was increased. Increased oxidative damage
may reﬂect either higher doses of the mitochondrial co-factors used in
this study or increased oxidative stress resulting from not counterba-
lancing mitochondrial cofactors with cellular antioxidants. Consistent
with this explanation, another smaller study demonstrated improved
short termmemory in aged beagles treatedwith a combination of phos-
phatidylserine, Ginkgo biloba, vitamin E and pyridoxine [120].
4. Summary
Using the canine model of aging, we show that providing a broad
spectrum of cellular antioxidants and mitochondrial co-factors withina specially-formulated food leads to signiﬁcant beneﬁts to cognition
and maintenance of function at doses that were well within those
used in human clinical trials. In addition, combining an antioxidant
enriched diet with cognitive training, physical exercise and social en-
richment provides additional beneﬁts to cognition. Future studies in
humans may be more efﬁcacious if combinations of antioxidants are
evaluated in parallel with additional lifestyle improvements (e.g. so-
cial engagement, cognitive training and physical exercise).
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